First major study to track babies exposed to rare disease drug in the womb
NCT ID NCT05579548
Summary
This study aims to gather safety information on the PKU drug Palynziq (pegvaliase) when used during pregnancy and breastfeeding. Researchers will follow about 50 pregnant women with PKU who are already taking the drug and track the health of both the mothers and their babies for about 21 months. The goal is to understand if the medication affects pregnancy outcomes or infant development.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHENYLKETONURIA, MATERNAL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Metabolics and Genetics in Calgary (MAGIC)
RECRUITINGCalgary, T2E 7Z4, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ospedale San Paolo
RECRUITINGMilan, 20142, Italy
Contact Email: •••••@•••••
-
Syneos Health
RECRUITINGWilmington, North Carolina, 28403, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Universitaetsklinikum Hamburg Eppendorf
RECRUITINGHamburg, 20246, Germany
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.